Navigation Links
Synbiotics Corporation Announces Human Submission for FluDetect(R)
Date:3/13/2008

KANSAS CITY, Mo., March 13 /PRNewswire/ -- Synbiotics Corporation today announced that it is seeking 510(k) authorization from the Food & Drug Administration (FDA) for the use of its FluDetect(R) Avian Influenza Virus rapid test strip in humans. This represents Synbiotics first foray into the human point-of-care diagnostic marketplace. While it is not Synbiotics' initial intent to market this product itself to the human field, it is actively seeking an established strategic human diagnostic partner, to market, sell and distribute this product.

Currently, the FluDetect(R) product is the only USDA approved rapid point of care test for avian influenza in the veterinary field. FluDetect(R) has been heralded for its extreme sensitivity in a simple to use test format that requires no equipment, nor extensive training to perform. Management believes this may be the first crossover test to be licensed for use both in humans and animals and can be a vital tool to healthcare institutions for both seasonal flu testing as well as in endemic situations.

"The feedback we have received on the outstanding field performance of FluDetect(R) in avian influenza has encouraged us to seek human use," said Paul Hays, Synbiotics' President & Chief Executive Officer. "It is our goal to find a partner in a timely fashion to be prepared to enter the human market for the 2008-2009 flu season," said Hays. Inquiries by potential partners should be made to Ronan Molloy at ronanm@synbiotics.com.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostic products for the poultry, livestock and companion animal markets worldwide. Synbiotics is an expert in avian influenza surveillance and early detection. Synbiotics manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the Company's website at http://www.synbiotics.com.

Contacts: Paul Hays

Synbiotics Corporation

1-816-464-3502


'/>"/>
SOURCE Synbiotics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
9. CEL-SCI Corporation Announces 2007 Financial Results
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and ... clinical and scientific initiatives have all marked the last 12 months at Roswell ... CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... your life? The answer may be at the tips of your toes. Foot massage, ... benefits as well as pure comfort and relaxation. The American Board of Multiple ...
(Date:2/5/2016)... Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight ... New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
Breaking Medicine News(10 mins):